Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 05 tags : Breast cancer save search
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Published: 2022-05-05 (Crawled : 12:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: -1.2%
enhertu approved cancer breast cancer her2- her2 metastatic breast cancer
Asia Breast Cancer Screening Market Report 2021-2027: China Holds Significant Dominance with with Mammogram Screening Leading the Market
Published: 2022-05-05 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 0.18%
H: 0.46%
C: 0.46%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.98%
H: 0.0%
C: -2.72%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.98%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
report china cancer market breast cancer
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: -1.2%
enhertu approved positive cancer breast cancer her2- her2 metastatic breast cancer
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.